Lumosa Therapeutics Co., Ltd.

Taipei Exchange 6535.TWO

Lumosa Therapeutics Co., Ltd. Price to Earnings Ratio (P/E) on January 14, 2025: -174.82

Lumosa Therapeutics Co., Ltd. Price to Earnings Ratio (P/E) is -174.82 on January 14, 2025, a NA change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Lumosa Therapeutics Co., Ltd. 52-week high Price to Earnings Ratio (P/E) is -114.41 on December 16, 2024, which is 34.55% above the current Price to Earnings Ratio (P/E).
  • Lumosa Therapeutics Co., Ltd. 52-week low Price to Earnings Ratio (P/E) is -255.89 on October 28, 2024, which is -46.38% below the current Price to Earnings Ratio (P/E).
  • Lumosa Therapeutics Co., Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is -182.35.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
Taipei Exchange: 6535.TWO

Lumosa Therapeutics Co., Ltd.

CEO Li Fang Pan
IPO Date July 16, 2015
Location
Headquarters No. 3-2, Park Street
Employees 47
Sector Health Care
Industries
Description

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.

StockViz Staff

January 15, 2025

Any question? Send us an email